GFACX
Price
$61.91
Change
-$1.33 (-2.10%)
Updated
Sep 6 closing price
NGDCX
Price
$26.04
Change
-$0.50 (-1.88%)
Updated
Sep 6 closing price
Ad is loading...

GFACX vs NGDCX

Header iconGFACX vs NGDCX Comparison
Open Charts GFACX vs NGDCXBanner chart's image
American Funds Growth Fund of Amer C
Price$61.91
Change-$1.33 (-2.10%)
VolumeN/A
CapitalizationN/A
Neuberger Berman Large Cap Growth C
Price$26.04
Change-$0.50 (-1.88%)
VolumeN/A
CapitalizationN/A
View a ticker or compare two or three
GFACX vs NGDCX Comparison Chart
Loading...
VS
GFACX vs. NGDCX commentary
Sep 08, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is GFACX is a Buy and NGDCX is a Buy.

FUNDAMENTALS
Fundamentals
GFACX has more cash in the bank: 270B vs. NGDCX (2.4B). GFACX (0.00) and NGDCX (0.00) have matching dividends . GFACX was incepted earlier than NGDCX: GFACX (24 years) vs NGDCX (15 years). NGDCX is a more actively managed with annual turnover of: 35.00 vs. GFACX (31.00). GFACX has a lower initial minimum investment than NGDCX: GFACX (250) vs NGDCX (1000). GFACX (16.44) and NGDCX (15.84) have marching annual gain over last year. NGDCX return over 5 years is better than : 44.24 vs. GFACX (38.56).
GFACXNGDCXGFACX / NGDCX
Total Expense RatioN/AN/A-
Annual Report Gross Expense RatioN/AN/A-
Fund Existence24 years15 years-
Gain YTD14.98212.220123%
Front LoadN/AN/A-
Min. Initial Investment250100025%
Min. Initial Investment IRAN/AN/A-
Net Assets270B2.4B11,269%
Annual Yield % from dividends0.000.00-
Returns for 1 year16.4415.84104%
Returns for 3 years-11.08-7.88141%
Returns for 5 years38.5644.2487%
Returns for 10 years42.4615.62272%
View a ticker or compare two or three
Ad is loading...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
KW11.040.03
+0.27%
Kennedy-Wilson Holdings
CTVA55.11-0.39
-0.70%
Corteva
FIVN29.58-0.24
-0.80%
Five9
VEV0.14N/A
-1.68%
Vicinity Motor Corp
ADAP1.11-0.05
-4.31%
Adaptimmune Therapeutics plc